Further studies elucidating the mechanism of tumor evasion from CTL cytotoxicity and the development of appropriate protocols for TLR3 adjuvant therapy would prove useful in this field to allow for complete tumor regression in cancer patients. This evidence concerns the gene TLR3 and cancer.